Further, ovarian cancers were suppressed by targeting Th2-biased inflammatory response, such as IL-4R-targeted therapies [23,24] or by using therapies that shift the immunosuppressive Th2 inflammation to the immunostimulatory Th1 type [35]. Here, IL4R is linked to ovarian cancer.